The impact of the restatement and other corrections on the condensed Consolidated Balance Sheet, Consolidated Statement of Operations and Consolidated Statement of Cash Flows as of and for the three month periods ended March 31, 2016 and March 31, 2015 is presented below, in thousands except share and per share data.

Three Months Ended March 31, 2016

Consolidated Statement of Operations	As Previously			Restatement			Other
(unaudited)	Reported			Adjustments			Corrections		As Restated

Royalty revenue	$	—		$	1,119		$		$	1,119
Total revenue	43,075			1,119					44,194
Operating income	5,318			1,119					6,437
Interest expense — non-recourse liability related to sale of future royalties	—			(1,279		)			(1,279		)
Total other expense	(133		)	(1,279		)			(1,412		)
Earnings before income taxes	5,185			(160		)			5,025
Income tax expense	198						2		200
Net income	4,987			(160		)	(2	)	4,825

Three Months Ended March 31, 2016

	As Previously			Restatement	Other
Consolidated Statements of Cash Flows (unaudited)	Reported			Adjustments	Corrections		As Restated

Net cash used in investing activities	$	(11,304	)		$	654	$	(10,650	)
Net change in cash and cash equivalents	(14,322		)		654		(13,668		)

As of March 31, 2016

	As Previously			Restatement		Other
Consolidated Balance Sheet (unaudited)	Reported			Adjustments		Corrections			As Restated

Accrued expenses	$	22,573				$	342		$	22,915
Non-recourse liability related to sale of future royalties — current portion	—			1,067					1,067
Total current liabilities	54,124			1,067		342			55,533
Non-recourse liability related to sale of future royalties — long term	—			29,621					29,621
Total liabilities	66,335			30,688		342			97,365
Accumulated deficit	(139,654		)	(30,688	)	(342		)	(170,684		)
Total stockholders’ equity	128,139			(30,688	)	(342		)	97,109

Three Months Ended March 31, 2015

Consolidated Statement of Operations	As Previously			Restatement			Other
(unaudited)	Reported			Adjustments			Corrections		As Restated

Royalty revenue	$	—		$	605		$		$	605
Total revenue	28,133			605					28,738
Selling, general and administrative	19,402						1		19,403
Total costs and expenses	24,703						1		24,704
Operating income	3,430			605			(1	)	4,034
Interest expense — non-recourse liability related to sale of future royalties	—			(759		)			(759		)
Total other expense	(2,451		)	(759		)			(3,210		)
Earnings before income taxes	979			(154		)	(1	)	824
Income tax expense	62						24		86
Net Income	917			(154		)	(25	)	738

Three Months Ended March 31, 2015

	As Previously			Restatement	Other
Consolidated Statements of Cash Flows (unaudited)	Reported			Adjustments	Corrections			As Restated

Net cash provided by (used in) operating activities	$	503			$	(768	)	$	(265	)
Net cash used in investing activities	(11,236		)		116			(11,120		)
Net change in cash and cash equivalents	(10,586		)		(652		)	(11,238		)

As of March 31, 2015

	As Previously			Restatement		Other
Consolidated Balance Sheet (unaudited)	Reported			Adjustments		Corrections			As Restated

Cash and cash equivalents	$	25,810				$	(652	)	$	25,158
Marketable securities	39,026					652			39,678
Accrued expenses	15,828					654			16,482
Total current liabilities	26,855					654			27,509
Non-recourse liability related to sale of future royalties — long term	—			30,179					30,179
Total liabilities	45,053			30,179		422			75,654
Additional paid-in capital	252,341					142			252,483
Accumulated deficit	(157,740		)	(30,179	)	(796		)	(188,715		)
Total stockholders’ equity	94,584			(30,179	)	(654		)	63,751

As of December 31, 2015

	As Previously			Restatement		Other
Consolidated Balance Sheet	Reported			Adjustments		Corrections			As Restated

Cash and cash equivalents	$	34,152				$	(654	)	$	33,498
Marketable securities	28,038					654			28,692
Accrued expenses	24,813					340			25,153
Non-recourse liability related to sale of future royalties — current portion	—			497					497
Total current liabilities	56,097			497		340			56,934
Non-recourse liability related to sale of future royalties — long term	—			30,031					30,031
Total liabilities	69,751			30,528		340			100,619
Accumulated deficit	(144,641		)	(30,528	)	(340		)	(175,509		)
Total stockholders’ equity	118,875			(30,528	)	(340		)	88,007